Stocklytics Platform
Asset logo for symbol NXL
Nexalin Technology
NXL48
$3.85arrow_drop_down9.47%-$0.39
Penny Stock
Asset logo for symbol NXL
NXL48

$3.85

arrow_drop_down9.47%

Performance History

Chart placeholder
Key Stats
Open$4.10
Prev. Close$4.10
EPS-0.65
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$54.27M
PE Ratio-
LOWHIGH
Day Range3.83
4.33
52 Week Range0.25
4.35
Ratios
Revenue-
EBITDA Margin %-
EPS-0.65

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Nexalin Technology (NXL)

NEXALIN TECHNOLOGY INC., a Nevada corporation (the "Company" or "Nexalin"), is an emerging growth company specializing in the development and commercialization of advanced medical devices and equipment. The Company is focused on the innovative treatment of mental health disorders through its proprietary Nexalin therapy system. Nexalin therapy is a non-invasive neuromodulation therapy that uses gentle electrical stimulation to the brain to alleviate symptoms of depression, anxiety, and insomnia.
The Nexalin therapy system has been clinically proven to effectively treat a wide range of mood and sleep disorders, including major depressive disorder, bipolar disorder, post-traumatic stress disorder, and chronic insomnia. Unlike traditional treatments such as medication and psychotherapy, Nexalin therapy is drug-free, painless, and has no known side effects. The therapy works by stimulating the production of neurotransmitters in the brain, which are chemicals that help regulate mood and sleep patterns.
Websitecall_made
Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Mark White
Headquarters
Houston
Employees
6
Exchange
NASDAQ
add Nexalin Technology to watchlist

Keep an eye on Nexalin Technology

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Nexalin Technology 's (NXL) price per share?

The current price per share for Nexalin Technology (NXL) is $3.86. The stock has seen a price change of -$0.4 recently, indicating a -9.48% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Nexalin Technology (NXL)?

For Nexalin Technology (NXL), the 52-week high is $4.35, which is 12.83% from the current price. The 52-week low is $0.25, the current price is 1.43K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Nexalin Technology (NXL) a growth stock?

Nexalin Technology (NXL) has shown an average price growth of -6.8% over the past three years. It has received a score of 0 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Nexalin Technology as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Nexalin Technology (NXL) stock price performance year to date (YTD)?

As of the latest data, Nexalin Technology (NXL) has a year-to-date price change of 868.87%. Over the past month, the stock has experienced a price change of 192.35%. Over the last three months, the change has been 292.13%. Over the past six months, the figure is 194.58%.
help

Is Nexalin Technology (NXL) a profitable company?

Nexalin Technology (NXL) has a net income of -$4.65M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 76.8% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -4.83K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $85.06K. Operating income is noted at -$5.7M. Furthermore, the EBITDA is -$6.4M.
help

What is the market capitalization of Nexalin Technology (NXL)?

Nexalin Technology (NXL) has a market capitalization of $49.45M. The average daily trading volume is 3.87, indicating the stock's liquidity and investor engagement.

News

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
NEXALIN TECHNOLOGY
NEUROSTIMULATION
MENTAL HEALTH
NEUROLOGICAL DISORDERS
Nov 1, 2024

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
NEXALIN TECHNOLOGY
UC SAN DIEGO
SAN DIEGO VA
GEN-3 HALO HEADSET
MILD TRAUMATIC BRAIN INJURY
VIRTUAL CLINIC
Oct 22, 2024

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Nexalin Technology Announces Closing of $5.2 Million Public Offering
ADVISORY
Jul 1, 2024

Nexalin Technology Announces Closing of $5.2 Million Public Offering

Nexalin Technology Announces Pricing of $5.2 Million Public Offering
INITIAL PUBLIC OFFERINGS
Jun 28, 2024

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
ADVISORY
Jun 20, 2024

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
ADVISORY
PRODUCT / SERVICES ANNOUNCEMENT
Jun 13, 2024

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

Take Your Investments to a Whole New Level